We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » In Latest Salvo Over Dueling Cholesterol-Fighting Antibodies, Regeneron Files New Antitrust Suit Against Amgen
In Latest Salvo Over Dueling Cholesterol-Fighting Antibodies, Regeneron Files New Antitrust Suit Against Amgen
In the latest move in the ongoing feud over their cholesterol-fighting monoclonal antibodies, Regeneron has filed a new antitrust suit against Amgen, accusing the drugmaker of carrying out an “unlawful, anticompetitive bundling scheme” to harm the market for Regeneron’s Praluent (alirocumab) in order to increase sales of Amgen’s competitor product, Repatha (evolocumab).